Dr. Haitao Lyu is an Associate Professor (tenured) at the School of Chinese Medicine, Hong Kong Baptist University. He also holds the position of Principal Investigator (PI) at the State Key Laboratory of Environmental and Biological Analysis (HKBU) and at the National Laboratory of Diseases and Omics. Dr. Lyu is the Deputy Director, Guangzhou-Hong Kong-Macau Universities Joint Laboratory of Interventional Medicine. Dr. Lyu is a research professor at the Hong Kong Baptist University Shenzhen Research Institute, an elected member of The European Academy of Sciences and Arts and a Fellow of the Royal Society of Chemistry (FRSC) and the Royal Society of Biology (FRSB). He is recognized as a Faculty Opinions (F1000 Prime) expert, and a visiting professorship in Haihe Laboratory of Modern Chinese Medicine (Tianjin, China). In addition, he is the Chief Expert at the Shanghai Academy of Science and Technology Expert Workstation. Previously, Dr. Lyu held the position of principal investigator (tenured) and PhD supervisor at the Institute of Systems Biomedicine at Shanghai Jiao Tong University. He also served as a principal investigator, PhD supervisor, and assistant dean at the Innovative Drug Research Center of the School of Pharmacy at Chongqing University. Earlier in his career, he worked as a postdoctoral research fellow at the Albert Einstein College of Medicine, the Washington University School of Medicine, and the Massachusetts Institute of Technology (SMART Center). Dr. Lyu's primary research focus lies in the application of cross-disciplinary sciences in life and health, driving the advancement of next-generation functional metabolomics research (STORM and STORM+). He has successfully led more than 16 projects, including the National Key R&D Program and the National Natural Science Foundation of China. His contributions to the field are evidenced by the publication of 60 SCI-indexed papers in authoritative journals within related fields, with 4 highly cited papers in the Essential Science Indicators (ESI). Dr. Lyu has co-edited one English book published by Wiley and one book on traditional Chinese medicine. Apart from his academic achievements, Dr. Lyu holds various positions of responsibility. He serves as the Deputy Secretary-General of the Metabolomics Committee of the Chinese Biophysical Society, The Vice Chairman of The Fangjiomics Speciality Committee of Chinese Pharmaceutical Association, the Deputy Secretary-General of the Network Pharmacology Committee of the Chinese Pharmacological Society, and The Vice Chairman of the Drug Metabolism Committee of the Guangdong Pharmacological Society. Furthermore, he actively contributes to the scientific community as an editor for Pharmacological Research (Section), Associate Editor for Royal Society Open Science, former Associate Editor for Phytomedicine, and an editorial board member for Proteomics. His expertise is also sought after as an expert reviewer for the National Natural Science Foundation of China and the Hong Kong Health and Medical Research Fund. Dr. Lyu's outstanding contributions have been recognized through several prestigious awards, including the 2021 Agilent Technologies Global Competitive ACT-UR Award, the 2022 Faculty Opinions Member of The Year Award, the 2013 QUT Vice Chancellor Research Fellowship, the 2022 APSB Outstanding Young Editorial Board Member Award, 2023 The Outstanding Editorial Board Member Award (Chinese Medicine Journal).

香港浸會大學中醫藥學院副教授(終身教席)/博士生導師，歐洲科學與人文學院院士，英國皇家化學會會士，河南省特聘研究員（海外），香港中醫藥表型組學研究中心副主任，介入醫學粵港澳高校聯合實驗室副主任，環境與生物分析國家重點實驗室PI, 疾病與組學全國重點實驗室PI，澳門科技大學兼職教授/博士生導師，現代中醫藥海河實驗室客座教授，上海院士專家工作站（專家級）首席專家，世界五百強丹納赫集團中國生命科學委員會顧問專家。曾任上海交通大學長聘教授/功能代謝組科學實驗室主任。長期從事生命健康交叉科學應用驅動的下一代功能代謝組學研究。主持國家重點研發計劃等16項基金，權威雜誌發表SCI論文60篇，ESI高被引4篇。任中國藥學會方劑組學專委會副主任委員、中國藥理學會網絡藥理學專委會副秘書長和、中國生物物理學會代謝組學分會副秘書長和廣東省藥理學會藥物代謝專委會副主任委員等；任Pharmacological Research-Section主編，Royal Society Open Science副主編；Phytomedicine前副主編，安捷倫全球競爭性ACT-UR Award和QUT Vice Chancellor Fellowship獲得者。國家科技部重點研發計劃和重大人才計劃終審專家。